Louise Skau Rasmussen

Louise Skau Rasmussen

Auto-generated profile, based on publicly available information

Louise Skau Rasmussen

Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
LRLouise S. Rasmussen
Louise S. Rasmussen
MYMette K. Yilmaz
Mette K. Yilmaz
UFUrsula G. Falkmer
Ursula G. Falkmer
LPLaurids Ø. Poulsen
Laurids Ø. Poulsen
MBMartin Bøgsted
Martin Bøgsted
JJJulia Sidenius Johansen
Julia Sidenius Johansen

1 April 2020 in European Journal of Cancer
Verified
Journal Article
Closed access
LRLouise S. Rasmussen
Louise S. Rasmussen
CFClaus Fristrup
Claus Fristrup
BJBenny V. Jensen
Benny V. Jensen
PPPer Pfeiffer
Per Pfeiffer
BWBritta Weber
Britta Weber
UFUrsula Gerda Falkmer
Ursula Gerda Falkmer

1 January 2020 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
ICInna Markovna Markovna Chen
Inna Markovna Markovna Chen
AJAstrid Z. Johansen
Astrid Z. Johansen
CDChristian Dehlendorff
Christian Dehlendorff
BJBenny V. Jensen
Benny V. Jensen
SBStig E. Bojesen
Stig E. Bojesen
JJJulia S. Johansen
Julia S. Johansen
Background: IL6 and YKL-40 (also known as chitinase 3-like 1 protein, CHI3L1) are produced by pancreatic cancer cells and macrophages and activate inflammation. C-reactive protein (CRP) is synthesized mainly in hepatic cells and primarily stimulated by IL6. The aim of this study was to determine the prognostic value of combined detection of serum IL6, YKL-40, and CRP in patients with pancreatic cancer receiving palliative chemotherapy. Methods: In all, 592 patients with unresectable pancreatic cancer from five hospitals in Denmark were included in the BIOPAC biomarker study between 2008 and 2017. Pretreatment and longitudinal serum values of IL6 and YKL-40 were determined. Baseline CRP and CA19-9 values were available for the whole cohort. Patients were dichotomized as low versus high using cutoffs for IL6 of >4.92 pg/mL, YKL-40 of >95% age-corrected percentile, and CRP of >10 mg/L. The main outcome was overall survival. Results: Combined elevations of serum IL6, YKL-40, and CRP were associated with worse survival in contrast to an isolated high concentration of a single marker. Serum IL6, YKL-40, and CRP were higher in patients with advanced stage disease and in patients with poor performance status. Higher IL6 and YKL-40 levels at the time of tumor progression and serum IL6 measured over time were associated with shorter overall survival. Conclusions: Combined high baseline serum levels of IL6, YKL-40, and CRP are associated with poor survival. Impact: Assessment of systemic inflammation via measurements of IL6, YKL-40, and CRP may be important for pancreatic cancer prognostication.

25 March 2019 in Acta Oncologica
Verified
Journal Article
Closed access
LRLouise Skau Rasmussen
Louise Skau Rasmussen
BVBenny Vittrup
Benny Vittrup
Morten LadekarlMorten Ladekarl
Morten Ladekarl
PPPer Pfeiffer
Per Pfeiffer
MYMette Karen Yilmaz
Mette Karen Yilmaz
CFClaus Fristrup
Claus Fristrup
Background: Adjuvant chemotherapy following curative resection is the standard treatment for pancreatic adenocarcinoma (PC). Randomized clinical trials using gemcitabine have shown a median overall survival (mOS) of 2 years and a 5-year survival rate of 15-20%. However, the effect of gemcitabine outside these trials is less clear. We examined the effect of postoperative gemcitabine on survival in an unselected cohort of patients receiving curative resection for PC in Denmark during a five-year period. Material and methods: From 1 May 2011 to 30 April 2016, 731 patients treated with curative resection were identified in the Danish Pancreatic Cancer Database (DPCD). Thirty patients died within 10 weeks postoperatively; 78 received other regimens or preoperative chemotherapy and were excluded. Of the remaining 623 patients, the chemotherapy (CT) group (n = 409, 66%) received gemcitabine within 10 weeks after resection, whereas the non-chemotherapy (NCT) group (n = 214, 34%) did not receive CT within 10 weeks. Results: CT patients were slightly younger than NCT patients but did not otherwise differ in baseline characteristics. The CT group showed a mOS of 24 months (95% CI; 21–27) and a 5-year survival rate of 22% (95% CI; 17–27); the NCT group had a mOS of 22 months (95% CI; 16–26, p = .27) and a 5-year survival rate of 26% (95% CI; 19–34, p = .66). Most patients (415/623) had lymph node metastases. Of these patients, those in the CT group (n = 280) had significantly longer mOS [20 months (95% CI; 18–24)] than those in the NCT group (n = 135) [14 months (95% CI; 11–17)]. Conclusions: In this national Danish cohort of PC patients undergoing resection between 2011 and 2016, the survival after postoperative gemcitabine was similar to that reported in previous clinical trials. However, the survival advantage of postoperative gemcitabine was limited to patients with lymph node metastases.

19 September 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
MSMette M. Steiniche
Mette M. Steiniche
SLSidsel Christy Lindgaard
Sidsel Christy Lindgaard
ICInna Markovna Markovna Chen
Inna Markovna Markovna Chen
JJJulia Sidenius Johansen
Julia Sidenius Johansen
RARikke Andersen
Rikke Andersen
KSKaren-Lise Spindler
Karen-Lise Spindler
Purpose: Changes in ctDNA levels during systemic treatment may predict treatment efficacy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), but quantitative response criteria are not yet established. This study evaluates our recently proposed ctDNA-RECIST. Experimental Design: Blood samples were collected before treatment, before the second treatment cycle, and at the time of the first CT evaluation from 220 patients with metastatic PDAC receiving first-line palliative chemotherapy. Plasma ctDNA levels were measured using Droplet Digital PCR with HOXA9 methylation assays. ctDNA response was determined according to ctDNA-RECIST and correlated with overall survival (OS). Results: ctDNA was positive before treatment in 71% of the patients and was related to OS [HR = 1.61; 95% confidence interval (CI), 1.19–2.19; P = 0.002]. Among ctDNA-positive patients, ctDNA maximal response (MR; n = 41) and ctDNA disease control (DC; n = 107) before the second treatment cycle had longer OS compared with ctDNA progressive disease (PD; n = 5; median OS: MR 11.9 months, DC 7.2 months, PD 3.6 months; P = 0.002). In Cox regression, ctDNA DC (HR = 1.55; 95% CI, 1.07–2.26; P = 0.021) and ctDNA PD (HR = 4.50; 95% CI, 1.74–11.6; P = 0.002) showed shorter OS compared with ctDNA MR. The same applied to ctDNA response at the time of the first CT evaluation assessed from the second treatment cycle (P < 0.001) and from treatment start (P < 0.001). Conclusions: ctDNA-RECIST applied to liquid biopsies holds potential for early evaluation of treatment benefit in patients with metastatic PDAC, offering a novel, minimally invasive method to guide early clinical decision-making. Future studies should validate ctDNA-RECIST prospectively, preferably in randomized controlled trials.

20 May 2021 in Pancreas
Verified
Journal Article
Closed access
LRLouise S. Rasmussen
Louise S. Rasmussen
CFClaus W. Fristrup
Claus W. Fristrup
BJBenny V. Jensen
Benny V. Jensen
PPPer Pfeiffer
Per Pfeiffer
BWBritta Weber
Britta Weber
UFUrsula G. Falkmer
Ursula G. Falkmer
Objectives: The aim of this study was to identify patterns of palliative chemotherapy (CTh) and the associated overall survival (OS) in patients with pancreatic cancer, with specific focus on age. Methods: Between May 1, 2011, and April 30, 2016, 4260 patients were registered in the Danish Pancreatic Cancer Database. The 1715 patients receiving palliative CTh were retrieved. Age was grouped into less than 70, 70 to less than 75, and 75 years or more. Results: Of the 1715 patients receiving first-line CTh, 586 (34%) underwent second-line CTh and 151 (9%) third-line CTh. First-line gemcitabine resulted in a significant worse survival compared with combination CTh, hazard ratio 1.51. For combination CTh, OS differed between the age groups, P < 0.01. The median OS in the less than 70 years (n = 547), 70 to less than 75 years (n = 163), and 75 years or more (n = 67) groups were 9.3, 9.6, and 7.2 months, respectively. No differences in survival were observed among patients receiving first-line gemcitabine (P = 0.35). Conclusions: Our findings are useful in treatment-related decision making in patients with pancreatic cancer. A significant survival benefit was observed for all patients after first-line combination CTh. The effect of combination CTh was most prominent among patients aged less than 75 years. By age, no differences in survival were observed in those receiving gemcitabine.